<i>Syzygium cumini</i>seed exhibits antidiabetic potential via multiple pathways involving inhibition of α‐glucosidase, DPP‐IV, glycation, and ameliorating glucose uptake in L6 cell lines

Syama, H. P.; Arun, K. B.; George, Sinumol; Dhanya, R.; Anusree, S.S.; Nisha, P.; Lankalapalli, Ravi S.; Sundaresan, A.; Jayamurthy, P.

doi:10.1111/jfpp.13464

Cited by 18 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… [ 121 ] Syzygium cumini (L.) Skeels (seeds) in vitro Inhibitory activity against α-glucosidase (IC 50 = 1.7 μg/mL) and α-amylase (IC 50 = 7.62 μg/mL). [ 122 ] Syzygium malaccense (L.) Merr. & L.M.Perry (leaves) in vitro Inhibitory activity against α-glucosidase (IC 50 = 15.52 μg/mL) and α-amylase (IC 50 = 147.30 μg/mL).…”

Section: Preclinical Pharmacological Activities Of Myricetinmentioning

confidence: 99%

Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications

Taheri

Suleria

Martins

et al. 2020

BMC Complement Med Ther

127

View full text Add to dashboard Cite

Several flavonoids have been recognized as nutraceuticals, and myricetin is a good example. Myricetin is commonly found in plants and their antimicrobial and antioxidant activities is well demonstrated. One of its beneficial biological effects is the neuroprotective activity, showing preclinical activities on Alzheimer, Parkinson, and Huntington diseases, and even in amyotrophic lateral sclerosis. Also, myricetin has revealed other biological activities, among them as antidiabetic, anticancer, immunomodulatory, cardiovascular, analgesic and antihypertensive. However, few clinical trials have been performed using myricetin as nutraceutical. Thus, this review provides new insights on myricetin preclinical pharmacological activities, and role in selected clinical trials.

show abstract

Section: Preclinical Pharmacological Activities Of Myricetinmentioning

confidence: 99%

Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications

Taheri

Suleria

Martins

et al. 2020

BMC Complement Med Ther

127

View full text Add to dashboard Cite

show abstract

“…Syama HP. et al [18] reported Syzygium cumini can potentially inhibit α-amylase, α-glucosidase, glycation, and DPP-IV enzymes. Ratsimamanga U. et al [16] reported Syzygium cumini exerts hypoglycemic action like sulfonylureas by stimulating the surviving β-cells to release more insulin.…”

Section: Fasting Blood Glucose Levels Mg/dlmentioning

confidence: 99%

Antihyperglycemic Activity of Syzygium cumini (Jamun) in Diabetic Rats

Kulkarni

Deshpande

Bhide

et al. 2021

JPRI

View full text Add to dashboard Cite

Background: Recently with the changes in population lifestyle, prediabetes is constantly on the rise. Management of prediabetes currently is with lifestyle modifications like weight loss, exercise and diet control. Better drugs with acceptable safety profile are needed for better control of prediabetes. This study was thus designed to evaluate the antihyperglycaemic effect of one such potential compound Syzygium cumini (SC) (Jamun)in comparison to conventional antidiabetic drug Metformin. Methods: Rats were divided into four study groups (SC 100mg/kg and 200 mg/kg, metformin 90 mg/kg and SC 200 mg/kg with metformin 90 mg/kg). The glycaemic changes were followed up for a period of 8 weeks. Results: Streptozotocin (STZ) induced significant rise in blood glucose levels in the rats. SC100 mg/kg and 200 mg/kg caused a reduction in BSL (192.50 ± 6.189 & 175.00 ± 6.782 respectively). SC 200 mg/kg alone and in combination with metformin caused a significant reduction in HbA1C levels at the end of 8th week (8.84 ± 0.65 &6.86 ± 0.40 respectively) as compared to their baseline levels. Increase in dose had led to more significant reduction in BSL at the end of 8th week in groups A & B (p < 0.05). However, reduction of BSL was superior with Metforminalone (159.17 ± 13.060) compared to Syzygium cumini administered alone. Also antihyperglycemic effect of Syzygium cumini administered along with metformin was significant (p < 0.05) compared to either doses of Syzygium cumini given alone. Conclusions: Syzygium cumini demonstratedantihyperglycemic activity in diabetic rats but less significant when compared to metformin. Antihyperglycaemic effect of Syzygium cumini with metformin was significantly better than either drugsgiven alone. In prediabetic or diabeticindividuals Syzygium cumini seed powdercan be suggested as a potential add-on therapy with conventional antidiabetic drugs. However more non-clinical and clinical studies need to be conducted to confirm the findings.

show abstract

“…Glucose uptake assay of SCE on L6 myoblast cells Glucose uptake activity of SCE was determined in differentiated L6 myoblast cells as per Takigawa-Imamura et al, and Syama et al (12,13). The cells were treated with non-toxic concentrations of SCE extract (10, 20, and 40 µg/mL) and insulin (positive control) at 100 nM.…”

Section: Determination Of Cell Viability For In Vitro Studiesmentioning

confidence: 99%

In vitro anti-diabetic activity, bioactive constituents, and molecular modeling studies with sulfonylurea receptor1 for insulin secretagogue activity of seed extract of Syzygium cumini (L.)

Aliyar

Nadig

Bharatham

2021

J Herbmed Pharmacol

View full text Add to dashboard Cite

Introduction: Syzygium cumini (L.) has been known to be used for diabetes treatment in traditional Indian and Chinese medicine. The present study focuses on the evaluation for glucose uptake and insulin release in vitro and characterization of phytoconstituents of the hydro-ethanolic extract of Syzygium cumini seed (SCE). Further, this report covers the molecular docking findings of the bioactive constituents on the sulfonylurea receptor 1 (SUR1). Methods: A glucose uptake assay of SCE was used to estimate the glucose uptake from the cell lysates and the cell culture supernatants using insulin as the reference standard. Insulin release activity of SCE from RIN-5F cells was estimated using enzyme-linked immunosorbent assay. The phytoconstituents were isolated by preparative HPLC and characterized by mass spectrometry, nuclear magnetic resonance (NMR) and infrared spectroscopy. The molecular docking of bioactive constituents was carried on repaglinide bound to the SUR1. Results: In the presence of SCE, the glucose uptake through L6 myoblast cells increased by 19.91% at 40 µg/mL in comparison with the vehicle control (P < 0.05). Moreover, SCE showed 2.8-fold enhancement of insulin release at 40 µg/mL as compared to the vehicle controls (P < 0.05). Gallic and ellagic acids were the key phytoconstituents isolated from SCE. Molecular docking studies revealed that both gallic acid and ellagic acid bind to the repaglinide binding pocket of SUR1. Conclusion: SCE increases the release of insulin and enhances glucose uptake in vitro, which may contribute to its in vivo anti-diabetic activity. The presence of ellagic acid and gallic acid in SCE may be the cause for enhanced insulin release observed with SCE following binding to SUR1.

show abstract

Syzygium cuminiseed exhibits antidiabetic potential via multiple pathways involving inhibition of α‐glucosidase, DPP‐IV, glycation, and ameliorating glucose uptake in L6 cell lines

Cited by 18 publications

References 26 publications

Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications

Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications

Antihyperglycemic Activity of Syzygium cumini (Jamun) in Diabetic Rats

In vitro anti-diabetic activity, bioactive constituents, and molecular modeling studies with sulfonylurea receptor1 for insulin secretagogue activity of seed extract of Syzygium cumini (L.)

Contact Info

Product

Resources

About